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Coronavirus Disease 2019 (COVID-19)
Criteria for Return to Work for Healthcare Personnel
with Confirmed or Suspected COVID-19 (Interim
Guidance)
Who this is for: Occupational health programs and public health officials making decisions about return to work for
healthcare personnel (HCP) with confirmed COVID-19, or who have suspected COVID-19 (e.g., developed symptoms of a
respiratory infection [e.g., cough, sore throat, shortness of breath, fever] but did not get tested for COVID-19).
Decisions about return to work for HCP with confirmed or suspected COVID-19 should be made in the context of local
circumstances. Options include a test-based strategy or a non-test-based strategy (i.e., time-since-illness-onset and time-
since-recovery strategy).
Return to Work Criteria for HCP with Confirmed or Suspected COVID-
19
Use one of the below strategies to determine when HCP may return to work in healthcare settings
1. Test-based strategy. Exclude from work until
Resolution of fever without the use of fever-reducing medications and
Improvement in respiratory symptoms (e.g., cough, shortness of breath), and
Negative results of an FDA Emergency Use Authorized molecular assay for COVID-19 from at least two
consecutive nasopharyngeal swab specimens collected ≥24 hours apart (total of two negative specimens)[1]
See Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens for 2019 Novel Coronavirus
(2019-nCoV).
2. Non-test-based strategy. Exclude from work until
At least 3 days (72 hours) have passed since recovery defined as resolution of fever without the use of fever-
reducing medications and improvement in respiratory symptoms (e.g., cough, shortness of breath); and,
At least 7 days have passed since symptoms first appeared
If HCP were never tested for COVID-19 but have an alternate diagnosis (e.g., tested positive for influenza), criteria for
return to work should be based on that diagnosis.
Return to Work Practices and Work Restrictions
CDC guidance for COVID-19 may be adapted by state and local health departments to respond to rapidly
changing local circumstances.
After returning to work, HCP should:
Wear a facemask at all times while in the healthcare facility until all symptoms are completely resolved or until 14
days after illness onset, whichever is longer
Be restricted from contact with severely immunocompromised patients (e.g., transplant, hematology-oncology) until
14 days after illness onset
Adhere to hand hygiene, respiratory hygiene, and cough etiquette in CDC’s interim infection control guidance (e.g.,
cover nose and mouth when coughing or sneezing, dispose of tissues in waste receptacles)
Self-monitor for symptoms, and seek re-evaluation from occupational health if respiratory symptoms recur or
worsen
Crisis Strategies to Mitigate Staffing Shortages
Healthcare systems, healthcare facilities, and the appropriate state, local, territorial, and/or tribal health authorities might
determine that the recommended approaches cannot be followed due to the need to mitigate HCP staffing shortages. In
such scenarios:
HCP should be evaluated by occupational health to determine appropriateness of earlier return to work than
recommended above
If HCP return to work earlier than recommended above, they should still adhere to the Return to Work Practices
and Work Restrictions recommendations above. For more information, see CDC’s Interim U.S. Guidance for Risk
Assessment and Public Health Management of Healthcare Personnel with Potential Exposure in a Healthcare Setting
to Patients with COVID-19.
Footnotes
All test results should be final before isolation is ended. Testing guidance is based upon limited information and is
subject to change as more information becomes available. In persons with a persistent productive cough, SARS-CoV-2-
RNA might be detected for longer periods in sputum specimens than in upper respiratory tract (nasopharyngeal swab)
specimens.
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